1. Home
  2. MBIO vs LABT Comparison

MBIO vs LABT Comparison

Compare MBIO & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.67

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$3.49

Market Cap

5.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MBIO
LABT
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
5.2M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
MBIO
LABT
Price
$0.67
$3.49
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
65.3K
312.8K
Earning Date
05-13-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
98.99
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$3.42
52 Week High
$7.00
$4.72

Technical Indicators

Market Signals
Indicator
MBIO
LABT
Relative Strength Index (RSI) 46.14 N/A
Support Level $0.58 N/A
Resistance Level $0.82 N/A
Average True Range (ATR) 0.08 0.00
MACD -0.00 0.00
Stochastic Oscillator 19.63 0.00

Price Performance

Historical Comparison
MBIO
LABT

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: